February 9, 2018 / 11:08 AM / 6 months ago

BRIEF-Boehringer Ingelheim Says Will Stop Testing Drug For Alzheimer's After Failed Trial

Feb 9 (Reuters) - Boehringer Ingelheim:

* BOEHRINGER INGELHEIM REFOCUSES PDE9 INHIBITION BRAIN RESEARCH ON SCHIZOPHRENIA FOLLOWING RESULTS FROM PHASE II ALZHEIMER’S TRIALS

* BOEHRINGER INGELHEIM - PHASE II ALZHEIMER’S DISEASE TRIALS WITH INVESTIGATIONAL COMPOUND BI 409306 HAD NOT MET EFFICACY ENDPOINTS

* BOEHRINGER INGELHEIM - PLANS FOR FURTHER TRIALS WITH BI 409306 IN AD WILL NOT BE PURSUED

* BOEHRINGER INGELHEIM - WILL REFOCUS EFFORTS ON ONGOING SCHIZOPHRENIA TRIALS WITH BI 409306 Source text for Eikon:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below